Tuesday, april 27 anatomy - Experimental Biology

tuesday
C117 966.6 Ramaline inhibits LPS-induced NO release in
macrophages by regulating MAPK and NF-kB activities. H-J.
Park, J.H. Yim and S. Pyo. Col. of Pharm., Sungkyunkwan
Univ., Republic of Korea and Korea Polar Res. Inst., Incheon.
C118 966.7 Histone deacetylases play a critical role in
regulating IFNa-mediated anti-HCV gene expression. S.
Mathews, F. Ademosu, S. Joshi-Barve, C. McClain and S.
Barve. Univ. of Louisville and Louisville VA Med. Ctr.
C119 966.8 An optimized method for paroxysmal nocturnal
hemoglobinuria screening flow cytometric diagnosis. A.M.
Peiro, N. Bastande, M.L. Fernández, J. Lucas, E. López-
Abadía and F. Tarín. Gen. Hosp. of Alicante, Spain.
C120 966.9 Ethanol inhibits lipid raft-dependent TCR
signaling and IL-2 expression: potential mechanism of alcoholinduced
immune suppression. S. Joshi-Barve, S. Ghare, M.
Patil, P. Hote, J. Suttles, C. McClain and S. Barve. Univ. of
Louisville and Louisville VA Med. Ctr.
C121 966.10 Metabolism of prostaglandin glyceryl esters by
human carboxylesterases, CES1 and CES2, and its inhibition
by bioactive metabolites of organophosphate insecticides. M.K.
Ross, A. Borazjani, P.M. Potter and S. Xie. Col. of Vet. Med.,
Mississippi State Univ. and St. Jude Children’s Hosp.
C122 966.11 Pharmacological evaluation of FL-6, a new
immunomodulatory drug, on coccidiosis in chickens. M.
Corbalá-Nava, G. Tellez, B. Hargis, L. Rodríguez-Fragoso
and J. Reyes-Esparza. Autonomous Univ. del Estado de
Morelos, Mexico and Univ. of Arkansas.
967. Drug Metabolism: Phase I and Phase II
Enzymes
Poster
Tu e. 7:30 a m—An a h e i m Co n v e n t i o n Ce n t e r, Ex h i b it Ha l l CD
Presentation time: 12:30 p m-2:45 p m
C123 967.1 Tecarfarin: a new oral anticoagulant and
the characterization of its in vitro metabolism using rat, dog,
and human hepatocytes. L. Lightning, P. Kumaraswamy,
R. Coleman, I. Irwin, M. Palme and P. Druzgala. ARYx
Therapeut., Fremont, CA.
C124 967.2 NMR-based structural model of rabbit
cytochrome P450 2B4 with the analgesic amidopyrine,
the intermediate desmethylamidopyrine, and its product
aminoantipyrine: implications for the structural basis of
sequential metabolism. A.G. Roberts, K. Vu and J.R. Halpert.
UCSD Skaggs Sch. of Pharm. and Pharmaceut. Sci. and
Sahlgrenska Acad., Univ. of Gothenburg, Sweden.
C125 967.3 Suppression of cytochrome P450 reductase
expression in hepatoma cells replicates the hepatic lipidosis
observed in hepatic reductase-null mice. T.D. Porter, S.
Banerjee and E.I. Stolarczyk. Univ. of Kentucky.
C126 967.4 Determination of mouse liver and lung Fmo
isoforms by absolute quantification. D.E. Williams, M.C.
Henderson, J.T. Morre and S.K. Krueger. Oregon State
Univ.
C127 967.5 Lack of substrate inhibition in a monomeric
form of human cytosolic SULT2A1. I.T. Cook, T. Leyh and C.
Falany. Univ. of Alabama at Birmingham and Albert Einstein
Col. of Med.
C128 967.6 Residence of p450 system enzymes in
endoplasmic reticular lipid microdomains. L. Brignac-Huber,
R. Reed and W.L. Backes. LSU Hlth. Sci. Ctr., Metairie and
New Orleans.
pHarmacology
C129 967.7 Studies on the subcellular location and
molecular mobility of human cytosolic sulfotransferase
SULT1C1 in living human embryonic kidney 293 cells. J.
Sheng. Massachusetts Col. of Pharm. and Hlth. Sci.
C130 967.8 Homology modeling and molecular dynamics
of CYP1A1 and CYP2B1 to explore aryl derivatives metabolism
by docking, followed by experimental assays. J.E. Mendieta-
Wejebe, J. Correa-Basurto, J.G. Trujillo-Ferrara and M.C.
Rosales-Hernández. Grad. Sch. of Med.-IPN, Mexico City.
C131 967.9 HPLC-UV analysis of bupropion and
hydroxybupropion: application to in vivo pharmacokinetic
drug-drug interaction studies between bupropion and potent
CYP2B6 inhibitors. A.L. Myers, J.C. Molnari, B.M. Moeller
and A.L. Myers. Drake Univ.
C132 967.10 Tecarfarin: a novel oral anticoagulant and
characterization of its pharmacokinetics, tissue distribution,
and mass balance in Sprague-Dawley rats. S. Rao, L. Shao,
I. Irwin, M. Palme and P. Druzgala. ARYx Therapeut. Inc.,
Fremont, CA.
C133 967.11 The effect of obesity on drug metabolism in
African-American children. M. Chiney and L.A.L. Johnson. Col.
of Pharm. and Sch. of Med., Univ. of Minnesota, Minneapolis.
C134 967.12 Human UDP-glucuronosyltransferases are
involved in the metabolism of the natural resveratrol analogues
arachidin-1, arachidin-3 and piceatannol. A. Radominska-
Pandya, V. Nair, S.M. Bratton, A.E. Gallus-Zawada, P.L.
Prather and F. Medina-Bolivar. Univ. of Arkansas for Med. Sci.
and Arkansas State Univ.
C135 967.13 Ligand-induced conformational changes
in cytochrome P450 2B4: a multi-technique approach. P.R.
Wilderman, S.C. Gay, A.G. Roberts, S. Li, T. Liu, V.L. Woods
and J.R. Halpert. Scaggs Sch. of Pharm. and Pharmaceut.
Sci. and Dept. of Med., UCSD.
C136 967.14 Structural importance of residue 334 in the
stability of cytochromes P450 2B6 and 2B11. J.C. Talakad,
P.R. Wilderman, D.R. Davydov, S. Kumar and J.R. Halpert.
Skaggs Sch. of Pharm. and Pharmaceut. Sci., UCSD and Univ.
of Missouri-Kansas City.
C137 967.15 Determinants of variability in divalproex
sodium (VPA) glucuronidation in children. J.S. Leeder, R.E.
Pearce, K.E. Price, R.M. Ward, J.F. Bale, F.S. Abbott, T.K.H.
Chang, M.J. Kennedy, J. Sullivan and A. Gaedigk. Children’s
Mercy Hosps. and Clins., Kansas City, MO, Univ. of Utah, Univ.
of British Columbia, Sch. of Pharm., Virginia Commonwealth
Univ. and Kosair Children’s Hosp., Louisville.
C138 967.16 Crystal structure of a cytochrome P450 2B6
genetic variant in complex with the inhibitor 4-(4-chlorophenyl)
imidazole at 2.0 Å resolution. S.C. Gay, M.B. Shah, J.C.
Talakad, K. Maekawa, A.G. Roberts, P.R. Wilderman, L.
Sun, J.Y. Yang, S.C. Huelga, Q. Zhang, C.D. Stout and J.R.
Halpert. UCSD, Univ. of Texas Med. Branch and The Scripps
Res. Inst.
C139 967.17 Mitochondrion is a novel site of biotransformation
of dichloroacetate by glutathione transferase zeta. W.
Li, M.O. James, S. McKenzie and P.W. Stacpoole. Univ. of
Florida.
t
u
e
295